Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Cilest to be discontinued

The manufacturer of Cilest® (norgestimate and ethinyl estradiol) has written to healthcare professionals advising that this product will be discontinued with effect from July 2019.

The letter states that this was a commercial decision to exit the oral hormonal contraceptive market and it is stressed that the are no safety, efficacy or quality issues with the product. Current supplies are expected to last until mid-July 2019.

There are two alternative products that are currently available in the UK with the same active ingredients - Cilique® and Lizinna®.

Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and arrangements made to identify a suitable alternative.

Share 'Cilest to be discontinued' on Email Share 'Cilest to be discontinued' on Delicious Share 'Cilest to be discontinued' on Digg Share 'Cilest to be discontinued' on Facebook Share 'Cilest to be discontinued' on reddit Share 'Cilest to be discontinued' on StumbleUpon Share 'Cilest to be discontinued' on Twitter

Drug Safety Update - November 2018

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for November 2018 (PDF).

This issue advises of a small increased risk non-melanoma skin cancer seen in association with hydrochlorothiazine. The risk is cumulative and dose-dependent and as such is seen more after long-term use. Patients taking such medicines should be advised to regularly check for and report any new or changed skin lesions or moles. Sensible exposure to sunlight and UV rays, including using adequate protection should also be advised. Use in patients with a history of skin cancers should be reconsidered.

This issue also reports a small increased risk of aortic aneurysm and dissection, particularly on older patients, using fluoroquinolones. These antibiotics should only be used after careful consideration in patients at risk of aortic aneurysm and dissection, for example those with a family history, pre-existing aortic aneurysm or dissection and diseases that increase the risk such as Marfan syndrome, Ehlers-Danlos syndrome and hypertension.

It is also reported that a clinical study of sildenafil (Revatio® and Viagra®) in early-onset intrauterine growth restriction has been terminated early after reports of persistent pulmonary hypertension of the newborn (PPHN). It is noted that sildenafil is not licensed for this condition and that Revatio is not recommended in pregnancy unless strictly necessary while Viagra is not authorised for use in women.

A Europe wide campaign is running from 19–23 November 2018 to support the safe use of medicines in babies, children, and pregnant and breastfeeding women. Social media will be used to discuss the importance of reporting suspected side effects via the Yellow Card Scheme.

Also this month, the summary of letters to healthcare professionals includes information about expiry date extension of Jext® adrenaline autoinjectors, a reminder of the advice about phenytoin (Epanutin®) 30mg/5ml oral suspension supply disruption and shortage of sodium valproate modified release (Epilim Chronosphere®▼). CoaguChek Test Strips have also been found to give false high readings and it is recommended that readings above 4.5 are confirmed using a laboratory method or unaffected batches of test strips before adjusting treatment.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - November 2018' on Email Share 'Drug Safety Update - November 2018' on Delicious Share 'Drug Safety Update - November 2018' on Digg Share 'Drug Safety Update - November 2018' on Facebook Share 'Drug Safety Update - November 2018' on reddit Share 'Drug Safety Update - November 2018' on StumbleUpon Share 'Drug Safety Update - November 2018' on Twitter

Guidance on cannabis-based products

NHS England has issued guidance on the use of cannabis-based products for medicinal use.

Following high-profile news stories over the summer, the Home Office reviewed the legal status of cannabis-based products for medicinal use. In light of evidence of therapeutic benefit in certain medical conditions these products will be rescheduled.

The guidance document notes that cannabis-based products for medicinal use should only be prescribed:

  • for indications where there is clear published evidence of benefit or UK
    Guidelines
  • where there is a clinical need which cannot be met by a licensed medicine
  • where established treatment options have been exhausted
  • under the prescription or direction of a specialist doctor (listed on the Specialist Register of the General Medical Council)

Action: Clinicians should be aware of this guidance. It essentially rules out prescribing in primary care and places restrictions on specialist prescribing.

Share 'Guidance on cannabis-based products' on Email Share 'Guidance on cannabis-based products' on Delicious Share 'Guidance on cannabis-based products' on Digg Share 'Guidance on cannabis-based products' on Facebook Share 'Guidance on cannabis-based products' on reddit Share 'Guidance on cannabis-based products' on StumbleUpon Share 'Guidance on cannabis-based products' on Twitter

CKS Updates - October 2018

During October 2018 Clinical Knowledge Summaries were published or updated in the following areas.

The following topics were all reviewed:

The majority of reviewed topics have undergone reviews and minor restructures.

The most significant changes were to the Bell's palsy topic where have been changes to the recommendations on use of antiviral treatment in combination with corticosteroids and referral and the Polycystic ovary syndrome topic where recommendations on the diagnosis of polycystic ovary syndrome (PCOS) in adolescents have been updated in line with guidance issued by the International PCOS Network.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - October 2018' on Email Share 'CKS Updates - October 2018' on Delicious Share 'CKS Updates - October 2018' on Digg Share 'CKS Updates - October 2018' on Facebook Share 'CKS Updates - October 2018' on reddit Share 'CKS Updates - October 2018' on StumbleUpon Share 'CKS Updates - October 2018' on Twitter

NICE Guidance - October 2018

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of October 2018. This month there are two guidelines that impact upon primary care.

The Lyme disease guideline has been updated correcting the information relating to treatments for Lyme carditis in children aged 9 to 12 who are haemodynamically unstable.

The Decision-making and mental capacity guideline has been published. It covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - October 2018' on Email Share 'NICE Guidance - October 2018' on Delicious Share 'NICE Guidance - October 2018' on Digg Share 'NICE Guidance - October 2018' on Facebook Share 'NICE Guidance - October 2018' on reddit Share 'NICE Guidance - October 2018' on StumbleUpon Share 'NICE Guidance - October 2018' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer